Clinical Laboratory Parameters in Adolescents with Moderate-to-Severe Atopic Dermatitis Treated with Tralokinumab Up to Week 52 in the Phase 3 ECZTRA 6 Trial [0.03%]
第3阶段ECZTRA 6研究中，度普利尤单抗治疗中至重度特应性皮炎青少年患者长达52周的临床实验室指标变化
Amy S Paller,Michael J Cork,H Chih-Ho Hong et al.
Amy S Paller et al.
Introduction: Tralokinumab is approved for the treatment of moderate-to-severe atopic dermatitis (AD) in patients aged ≥ 12 years. Here, we examined clinical laboratory parameters in adolescents with moderate-to-severe A...
Treatment Patterns and Economic Burden in Moderate to Severe Chronic Hand Eczema in the USA: A Real-World Retrospective Claims Analysis [0.03%]
美国中重度慢性手湿疹的治疗模式和经济负担：一项真实世界的回顾性索赔分析
April W Armstrong,Rebecca Burne,Aseel Bin Sawad et al.
April W Armstrong et al.
Introduction: Although Chronic Hand Eczema (CHE) is associated with substantial humanistic burden, treatment patterns and economic impact are poorly understood in the USA. Therefore, this study characterized real-world tr...
Tildrakizumab Improves Disease Severity and Patient-Reported Outcomes in Moderate-to-Severe Chronic Plaque Psoriasis: A Prospective Real-World Study [0.03%]
特立德珠单抗改善中重度慢性斑块状银屑病患者的疾病严重程度和患者报告结果：一项前瞻性真实世界研究
Paola Facheris,Francesco Piscazzi,Giovanni Fiorillo et al.
Paola Facheris et al.
Introduction: Chronic plaque psoriasis significantly impairs physical, psychological, and social well-being. Patient-reported outcome measures (PROMs) are increasingly recognized as essential endpoints. Tildrakizumab, an ...
Efficacy, Safety, and Tolerability of a Wearable Electrotrichogenic Device in Men with Androgenetic Alopecia: A Randomized, Double-Blind, Sham-Controlled Trial [0.03%]
穿戴式电毛发生发仪治疗男性雄激素性脱发的疗效、安全性和耐受性：随机双盲对照试验
Carlos A Chacón-Martínez,Gleb Pogorelov,Kin K Cabral et al.
Carlos A Chacón-Martínez et al.
Introduction: Androgenetic alopecia (AGA), the most common form of hereditary hair loss, is highly prevalent and commonly requires long-term, consistent treatment. This randomized controlled trial evaluated the efficacy, ...
Real-World Use of Baricitinib in Patients with Atopic Dermatitis in Spain: DAMA-S Study, A Retrospective Chart Review [0.03%]
巴利昔맙治疗西班牙特应性皮炎患者的真实世界研究（DAMA-S研究）：一项回顾性病历分析
Enrique Gómez de la Fuente,Enrique Herrera,Iñigo Martinez-Espronceda Esquerdo et al.
Enrique Gómez de la Fuente et al.
Introduction: Baricitinib has shown positive results in clinical trials both from efficacy and safety outcomes; however, there is still a need to further understand its use in routine practice in Spain. ...
Beyond the Skin: Assessing Itch in Atopic Dermatitis - Insights from UK Dermatologists. A Cross-Sectional Survey and Narrative Review [0.03%]
超越表象：英国皮肤科医生对特应性皮炎患者瘙痒的评估见解——横断面调查与叙述性综述
Philip Laws,Alberto Barea,Georgina Fremlin et al.
Philip Laws et al.
Background: Chronic itch is the most burdensome symptom of atopic dermatitis (AD), yet its routine assessment and measurement remain inconsistent. Objecti...
Efficacy and Safety of the PD-1 Agonist JNJ-67484703 in Participants with Atopic Dermatitis: Phase 2a, Randomized, Double-Blind, Placebo-Controlled Trial Results [0.03%]
JNJ-67484703（一种用于治疗特应性皮炎受试者的PD-1激动剂）2a期、随机、双盲、安慰剂对照试验疗效和安全性：临床试验结果
Michael Cecchini,Bartlomiej Kwiek,Fang Liu-Walsh et al.
Michael Cecchini et al.
Introduction: Atopic dermatitis (AD) is a chronic, inflammatory skin disease with a high burden and unmet needs. Herein, we have assessed the efficacy and safety of JNJ-67484703, a programmed cell death protein 1 (PD-1)-a...
Multidisciplinary Management in Psoriasis: A Structured Approach for Early Comorbidity Detection and Referral [0.03%]
银屑病的多学科管理：早期共病检测和转诊的结构化方法
Anna López-Ferrer,Álvaro González-Cantero,Ana Gutiérrez-Casbas et al.
Anna López-Ferrer et al.
Introduction: Psoriasis is a systemic disease with a high burden of underdiagnosed and undertreated comorbidities, partly due to fragmented care. These comorbidities significantly worsen outcomes and quality of life, high...
Early Proteomic Alterations in Non-segmental Vitiligo Skin Following Treatment with Topical Tacrolimus [0.03%]
他克莫司治疗非节段型白癜风皮损早期蛋白质组改变
Morten B Haulrig,Sonja Kabatnik,Lone Skov et al.
Morten B Haulrig et al.
Introduction: Vitiligo is a chronic depigmenting skin disease that can severely affect quality of life. First-line treatments include topical calcineurin inhibitors such as tacrolimus, but their molecular mechanisms of ac...
Summary of Research: Systemic Treatments in Moderate-to-Severe Atopic Dermatitis in Pediatric Patients up to 12 Years of Age: Real-World Treatment Outcomes from the PEDISTAD Registry [0.03%]
PEDISTAD登记研究的回顾：一项针对12岁以下中重度特应性皮炎患者系统治疗的真实世界疗效观察性研究
Amy S Paller,Danielle Marcoux,Michele Ramien et al.
Amy S Paller et al.
This is a summary of the original article "Systemic Treatments in Moderate-to-Severe Atopic Dermatitis in Pediatric Patients up to 12 Years of Age: Real-World Treatment Outcomes from the PEDISTAD Registry." Atopic dermatitis (AD, or eczema)...